These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 7542644

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Interleukin-2 killer cells: in vitro evaluation of combination with prothymosin alpha.
    López-Rodríguez JL, Cordero OJ, Sarandeses C, Viñuela J, Nogueira M.
    Lymphokine Cytokine Res; 1994 Jun; 13(3):175-82. PubMed ID: 7948426
    [Abstract] [Full Text] [Related]

  • 3. Differential oncolytic effect of NK-enriched subsets in long-term interleukin-2 cultures.
    Fuchshuber PR, Lotzová E.
    Lymphokine Cytokine Res; 1992 Oct; 11(5):271-6. PubMed ID: 1281676
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS, Simms PE, Helfrich BA, Fisher RI, Ellis TM.
    Cancer Res; 1992 Nov 15; 52(22):6318-22. PubMed ID: 1384959
    [Abstract] [Full Text] [Related]

  • 6. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
    Roussel E, Gerrard JM, Greenberg AH.
    Clin Exp Immunol; 1990 Nov 15; 82(2):416-21. PubMed ID: 1700746
    [Abstract] [Full Text] [Related]

  • 7. Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.
    Eckert K, Grünberg E, Immenschuh P, Garbin F, Kreuser ED, Maurer HR.
    J Cancer Res Clin Oncol; 1997 Nov 15; 123(8):420-8. PubMed ID: 9292704
    [Abstract] [Full Text] [Related]

  • 8. Prothymosin alpha enhances human natural killer cell cytotoxicity: role in mediating signals for NK activity.
    Cordero OJ, Sarandeses CS, López JL, Nogueira M.
    Lymphokine Cytokine Res; 1992 Oct 15; 11(5):277-85. PubMed ID: 1467368
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.
    Fuchshuber PR, Lotzová E, Pollock RE.
    Lymphokine Cytokine Res; 1991 Apr 15; 10(1-2):51-9. PubMed ID: 1651770
    [Abstract] [Full Text] [Related]

  • 10. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA, Pekle K, Gazzola MV, Collins NH, Gillio A.
    Cell Immunol; 1990 Mar 15; 126(1):211-26. PubMed ID: 1689220
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.
    Zupo S, Azzoni L, Massara R, D'Amato A, Perussia B, Ferrarini M.
    J Clin Immunol; 1993 May 15; 13(3):228-36. PubMed ID: 7686565
    [Abstract] [Full Text] [Related]

  • 14. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA, Pekle K, Gazzola MV, Collins NH, Bourhis JH, Gillio A.
    J Immunol; 1989 Nov 15; 143(10):3241-9. PubMed ID: 2809200
    [Abstract] [Full Text] [Related]

  • 15. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
    Bayle C, Vitté-Mony I, Lang P, Pico J, Hercend T, Bertoglio J.
    Leukemia; 1992 May 15; 6(5):470-6. PubMed ID: 1375700
    [Abstract] [Full Text] [Related]

  • 16. Antibodies to adhesion molecules inhibit the lytic function of MHC-unrestricted cytotoxic cells by preventing their activation.
    Zarcone D, Viale O, Cerruti G, Tenca C, Malorni W, Arancia G, Iosi F, Galandrini R, Velardi A, Moretta A.
    Cell Immunol; 1992 Sep 15; 143(2):389-404. PubMed ID: 1380897
    [Abstract] [Full Text] [Related]

  • 17. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
    Rabinowich H, Sedlmayr P, Herberman RB, Whiteside TL.
    Cell Immunol; 1991 Jul 15; 135(2):454-70. PubMed ID: 1709827
    [Abstract] [Full Text] [Related]

  • 18. CD16- CD56+ natural killer cells after bone marrow transplantation.
    Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE.
    Blood; 1992 Jun 15; 79(12):3239-44. PubMed ID: 1375847
    [Abstract] [Full Text] [Related]

  • 19. Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell subset that differentiates in vitro in the presence of interleukin 12.
    Bennett IM, Zatsepina O, Zamai L, Azzoni L, Mikheeva T, Perussia B.
    J Exp Med; 1996 Nov 01; 184(5):1845-56. PubMed ID: 8920872
    [Abstract] [Full Text] [Related]

  • 20. Expression of an early myelopoietic antigen (CD33) on a subset of human umbilical cord blood-derived natural killer cells.
    Handgretinger R, Schäfer HJ, Baur F, Frank D, Ottenlinger C, Bühring HJ, Niethammer D.
    Immunol Lett; 1993 Aug 01; 37(2-3):223-8. PubMed ID: 7505004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.